Narrow‐band UVB_311 nm vs. broad‐band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo

Abstract

After 7-16 weeks, six of the nine patients showed initial repigmentation on the side treated with UVB311 nm. After 6 months of treatment, none of the patients showed repigmentation on the areas treated with broad-band UVB, which prompted us to apply UVB311 nm all over the body. At the end of 12 months, two patients showed > 75% repigmentation, two showed 51-75%, two showed 26-50%, and three showed 0-25%. In all patients with progressive vitiligo (seven of the nine patients), disease activity was stopped. Remarkably, vitiligo lesions treated with calcipotriol initially showed delayed repigmentation compared with control areas; however, there was no therapeutic difference between calcipotriol and placebo, both in combination with UVB311 nm, by the end of the study. The DLQI score improved significantly by an average of 28%. Conclusion UVB311 nm therapy was effective in the treatment of vitiligo, whereas broad-band UVB had no effect. Combination with calcipotriol ointment was not superior to UVB311 nm monotherapy. The quality of life significantly improved with narrow-band UVB311 nm phototherapy.

Ultraviolet B (UVB) Phototherapy in the Treatment of Vitiligo

“…These receptors are also on T cells. Studies found that combination calcipotriol and NB-UVB therapy was not superior to NB-UVB alone (Ada, Sahin et al, 2005;Hartmann, Lurz et al, 2005). Similar findings were found when calcipotriene ointment and NB-UVB three times weekly were combined (Kullavanijaya and Lim, 2004).…”

“…Nearly 60% of patients had 80-100% repigmentation after 70 BB-UVB treatment sessions, a rate comparable to topical PUVA (55.6%) and NB-UVB (54.2%) treated patients in the same trial (El-Mofty, Mostafa et al, 2010). Other studies suggest that BB-UVB is less effective or had no effect compared to PUVA and NB-UVB phototherapy for the treatment of vitiligo (Hartmann, Lurz et al, 2005;Gawkrodger, Ormerod et al, 2008). Furthermore, targeted BB-UVB therapy was found to have limited effectiveness in vitiligo, and treatment-responsive areas were limited to the face (Akar, Tunca et al, 2009).…”

A Retrospective Study of Methylprednisolone Mini-Pulse Therapy Combined with Narrow-Band UVB in Non-Segmental Vitiligo

“…Repigmentation began to appear between 4 and a maximum of 8 weeks of treatment. Studies reporting the use of NBUVB monotherapy in vitiligo reported initial repigmentation after 7-16 weeks of treatment in one study [14] and after an average of 34 treatments or 17 weeks of therapy in the other [15]. In studies using NBUVB for the therapy of vitiligo, overall repigmentation rates of 41.6-100% were reported to occur [15,16,17,18,19,20], and only 9% showed more than 75% repigmentation [17].…”

Multicenter study of the efficacy of combination therapy of patients with vitiligo (narrowband phototherapy in combination with Vitiskin local antioxidant)

“…В последние годы одним из патогенетических методов лечения считают применение местных ан-тиоксидантов и УФ-В-терапию (UVB TL01) с дли-ной волны 311 нм [4,7,8]. Разработан гель Вити-скин, который содержит супероксиддисмутазу, спо-собствующую нейтрализации свободных радикалов, благодаря чему стимулируется общий метаболизм в клетках [4,7].…”